Related Experiment Videos

Neuroblastoma: inhibition of progression (Part II). Basic science in pediatric surgery

R Girgert1, J Wittrock, P Schweizer

  • 1Department of Pediatric Surgery, University of Tübingen, Germany. rainer.girgert@medizin.uni-ulm.de

Insights

Insulin-like growth factor II (IGF-II) promotes neuroblastoma growth by increasing N-myc expression. Farnesyl-protein transferase (FPTase) inhibitors reduce this growth and N-myc induction by blocking Ras signaling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Neuroblastoma is a pediatric cancer where N-myc gene amplification predicts poor patient outcomes.
  • Mechanisms regulating N-myc expression, crucial for neuroblastoma progression, are not fully understood.
  • Insulin-like growth factor II (IGF-II) has been implicated in promoting neuroblastoma growth.

Purpose of the Study:

  • To investigate the role of IGF-II in regulating N-myc expression in neuroblastoma.
  • To explore the potential of inhibiting Ras signaling pathways to counteract IGF-II-mediated N-myc induction and tumor growth.

Main Methods:

  • Utilized neuroblastoma cell lines with varying expression of IGF-II and IGF-receptor.
  • Stimulated receptor-positive cell lines with IGF-II to assess N-myc expression changes.
  • Treated cells with a farnesyl-protein transferase (FPTase) inhibitor to evaluate Ras protein inactivation and its effect on cell growth and IGF-II response.

Main Results:

  • IGF-II stimulation enhanced N-myc expression in neuroblastoma cells expressing the IGF-receptor.
  • FPTase inhibition led to complete inactivation of H-ras and significant inactivation of N-ras proteins.
  • FPTase inhibition diminished neuroblastoma cell growth and reduced the growth-promoting effect of IGF-II by 50%.

Conclusions:

  • IGF-II promotes neuroblastoma cell growth and N-myc expression, likely via the Ras signaling pathway.
  • Inhibition of FPTase represents a potential therapeutic strategy to reduce neuroblastoma proliferation by targeting Ras signaling and mitigating IGF-II effects.

Related Concept Videos